Improving clinical trials in the critically ill: Unique challenge—Sepsis
- 1 January 2009
- journal article
- review article
- Published by Ovid Technologies (Wolters Kluwer Health) in Critical Care Medicine
- Vol. 37 (Supplement), S117-S128
- https://doi.org/10.1097/ccm.0b013e318192078b
Abstract
This article aimed at providing suggestions to improve the success rate of future sepsis trials.Systematic review.None.CENTRAL (The Cochrane Library Issue 2, 2007) was searched using "sepsis" OR "severe sepsis" OR "septic shock" as search terms. The search was restricted to studies designed and conducted in adults with severe sepsis or septic shock after June 1992, published before September 2007, and powered for survival analysis. Twenty-seven trials were included and analyzed. The author suggested six key points for the design and conduct of future sepsis trials: 1) avoid mixing patients with severe sepsis and septic shock; 2) restrict time window to less than 24 hrs from onset of the first organ dysfunction or shock; 3) include only undisputable sepsis; 4) use the Sepsis-related Organ Failure Assessment score for eligibility; 5) include a first interim analysis after enrollment of 25% of the planned sample size to check the actual basal risk of death and to recalculate the number of patients needed; 6) strictly control for concomitant treatments on the basis of the Surviving Sepsis Campaign.There is a need to limit the sources of heterogeneity in sepsis trials by a better definition of target populations, by a better estimation of basal risk of death, and by controlling cointerventions.Keywords
This publication has 39 references indexed in Scilit:
- Septic shockThe Lancet, 2005
- EPISEPSIS: a reappraisal of the epidemiology and outcome of severe sepsis in French intensive care unitsIntensive Care Medicine, 2004
- Current Epidemiology of Septic ShockAmerican Journal of Respiratory and Critical Care Medicine, 2003
- The Epidemiology of Sepsis in the United States from 1979 through 2000New England Journal of Medicine, 2003
- 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions ConferenceCritical Care Medicine, 2003
- The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trialsThe Lancet, 2001
- Treatment of Severe Systemic Inflammatory Response Syndrome and Sepsis With a Novel Bradykinin Antagonist, Deltibant (CP-0127)Results of a Randomized, Double-blind, Placebo-Controlled TrialPublished by American Medical Association (AMA) ,1997
- INTERSEPTCritical Care Medicine, 1996
- Treatment of Septic Shock with the Tumor Necrosis Factor Receptor:Fc Fusion ProteinNew England Journal of Medicine, 1996
- American College of Chest Physicians/Society of Critical Care Medicine Consensus ConferenceCritical Care Medicine, 1992